Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2020

Open Access 01-02-2020 | Solid Tumor | Special Article

Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition

Authors: Saori Mishima, Hiroya Taniguchi, Kiwamu Akagi, Eishi Baba, Yutaka Fujiwara, Akira Hirasawa, Masafumi Ikeda, Osamu Maeda, Kei Muro, Hiroshi Nishihara, Hiroyki Nishiyama, Tadao Takano, Katsuya Tsuchihara, Yasushi Yatabe, Yasuhiro Kodera, Takayuki Yoshino

Published in: International Journal of Clinical Oncology | Issue 2/2020

Login to get access

Abstract

Background

Novel therapeutic agents have improved survival outcomes in patients with advanced solid tumors. In parallel, the development of predictive biomarkers to identify patients who are likely to benefit from a certain treatment has also contributed to the improvement of survival. Recently, clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. In Japan, a PD-1 inhibitor for dMMR advanced solid tumors, regardless of the primary tumor site, has been approved. However, there are some issues related to administering immune checkpoint inhibitors in the clinical practice setting, making it necessary to develop the guidelines.

Methods

Clinical questions (CQs) regarding medical care were formulated for patients with dMMR advanced solid tumors, and evidence to the CQs was collected by manual search to prepare recommendations. Then, the committee members voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other factors.

Results

The current guideline, which we consider a provisional clinical opinion at this point, describes the 11 requirements to be considered in terms of patients for whom dMMR testing is recommended, the timing and methods of dMMR testing, and clinical care systems required to perform dMMR testing properly and to administer immune checkpoint inhibitors safely.

Conclusion

This provisional clinical opinion proposes the requirements for performing dMMR testing properly to select patients who are likely to benefit from immune checkpoint inhibitors and administering them safely.
Appendix
Available only for authorised users
Literature
1.
Kuiper RP, Vissers LE, Venkatachalam R et al (2011) Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32(4):407–414PubMed
2.
Niessen RC, Hofstra RM, Westers H et al (2009) Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 48(8):737–744PubMed
3.
Goel A, Nguyen TP, Leung HC et al (2011) De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer 128(4):869–878PubMedPubMedCentral
4.
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932PubMed
5.
6.
McGivern A, Wynter CV, Whitehall VL et al (2004) Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 3(2):101–107PubMed
7.
Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413PubMedPubMedCentral
8.
Latham A, Srinivasan P, Kemel Y et al (2019) Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37(4):286–295PubMed
9.
Hause RJ, Pritchard CC, Shendure J et al (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22(11):1342–1350PubMed
10.
Funkhouser WK Jr, Lubin IM, Monzon FA et al (2012) Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the Association for Molecular Pathology. J Mol Diagn 14(2):91–103PubMed
11.
Asaka S, Arai Y, Nishimura Y et al (2009) Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes’ A to Dukes’ B. Carcinogenesis 30(3):494–499PubMed
12.
Ishikubo T, Nishimura Y, Yamaguchi K et al (2004) The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. Cancer Lett 216(1):55–62PubMed
13.
Fujiyoshi K, Yamamoto G, Takenoya T et al (2017) Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res 37(1):239–247PubMed
14.
Kajiwara T, Shitara K, Denda T et al (2016) The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)-GI-SCREEN 2013-01-CRC sub-study. J Clin Oncol. 34(suppl_15):abstr 3537
15.
Koinuma K, Shitoh K, Miyakura Y et al (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108(2):237–242PubMed
16.
An JY, Kim H, Cheong JH et al (2012) Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 131(2):505–511PubMed
17.
Yamamoto H, Perez-Piteira J, Yoshida T et al (1999) Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 116(6):1348–1357PubMed
18.
Choi YY, Bae JM, An JY et al (2014) Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol 110(2):129–135PubMed
19.
Schulmann K, Brasch FE, Kunstmann E et al (2005) HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 128(3):590–599PubMed
20.
Chiappini F, Gross-Goupil M, Saffroy R et al (2004) Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 25(4):541–547PubMed
21.
Goeppert B, Roessler S, Renner M et al (2019) Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 120(1):109–114PubMed
22.
Roa JC, Roa I, Correa P et al (2005) Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol 40(1):79–86PubMed
23.
Cloyd JM, Chun YS, Ikoma N et al (2018) Clinical and genetic implications of DNA mismatch repair deficiency in biliary tract cancers associated with Lynch syndrome. J Gastrointest Cancer 49(1):93–96PubMedPubMedCentral
24.
Yamamoto H, Itoh F, Nakamura H et al (2001) Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 61(7):3139–3144PubMed
25.
Humphris JL, Patch AM, Nones K et al (2017) Hypermutation in pancreatic cancer. Gastroenterology 152(1):68–74PubMed
26.
Cloyd JM, Katz MHG, Wang H et al (2017) Clinical and genetic implications of DNA mismatch repair deficiency in patients with pancreatic ductal adenocarcinoma. JAMA Surg 152(11):1086–1088PubMedPubMedCentral
27.
Hu ZI, Shia J, Stadler ZK et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24(6):1326–1336PubMedPubMedCentral
28.
Lupinacci RM, Goloudina A, Buhard O et al (2018) Prevalence of microsatellite instability in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 154(4):1061–1065PubMed
29.
Riazy M, Kalloger SE, Sheffield BS et al (2015) Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol 28(10):1383–1389PubMed
30.
Koornstra JJ, Mourits MJ, Sijmons RH et al (2009) Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 10(4):400–408PubMed
31.
Pal T, Permuth-Wey J, Kumar A et al (2008) Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res 14(21):6847–6854PubMedPubMedCentral
32.
Goodfellow PJ, Buttin BM, Herzog TJ et al (2003) Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 100(10):5908–5913PubMedPubMedCentral
33.
Kim J, Kong JK, Yang W et al (2018) DNA mismatch repair protein immunohistochemistry and MLH1 promotor methylation testing for practical molecular classification and the prediction of prognosis in endometrial cancer. Cancers 10(9):E279PubMed
34.
Barrow E, Robinson L, Alduaij W et al (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75(2):141–149PubMed
35.
Dowty JG, Win AK, Buchanan DD et al (2013) Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34(3):490–497PubMed
36.
Hirasawa A, Imoto I, Naruto T et al (2017) Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget 8(68):112258–112267PubMedPubMedCentral
37.
Bonadona V, Bonaïti B, Olschwang S et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304–2310PubMed
38.
Baglietto L, Lindor NM, Dowty JG et al (2010) Dutch Lynch Syndrome Study Group. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102(3):193–201PubMedPubMedCentral
39.
Huang D, Matin SF, Lawrentschuk N et al (2018) Systematic review: an update on the spectrum of urological malignancies in Lynch syndrome. Bladder Cancer 4(3):261–268PubMedPubMedCentral
40.
Harper HL, McKenney JK, Heald B et al (2017) Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol 30(1):146–156PubMed
41.
Therkildsen C, Eriksson P, Höglund M et al (2018) Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol 12(8):1286–1295PubMedPubMedCentral
42.
Brennetot C, Buhard O, Jourdan F et al (2005) Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumours and predict tumor content: implications for population screening. Int J Cancer 113(3):446–450PubMed
43.
Bando H, Okamoto W, Fukui T et al (2018) Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Sci 109(11):3411–3415PubMedPubMedCentral
44.
Patil DT, Bronner MP, Portier BP et al (2012) A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA. Diagn Mol Pathol 21(3):127–133PubMed
45.
Wang Y, Shi C, Eisenberg R et al (2017) Differences in microsatellite instability profiles between endometrioid and colorectal cancers: a potential cause for false-negative results? J Mol Diagn 19(1):57–64PubMedPubMedCentral
46.
Shia J, Tang LH, Vakiani E et al (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33(11):1639–1645PubMed
47.
Hempelmann JA, Scroggins SM, Pritchard CC et al (2015) MSIplus for integrated colorectal cancer molecular testing by next-generation sequencing. J Mol Diagn 17(6):705–714PubMed
48.
FoundationOne SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED)
49.
50.
51.
Haraldsdottir S, Roth R, Pearlman R et al (2016) Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. Fam Cancer 15(2):253–260PubMed
52.
Barnetson R, Eckstein R, Robinson B et al (2003) There is no increase in frequency of somatic mutations in metastases compared with primary colorectal carcinomas with microsatellite instability. Genes Chromosomes Cancer 38(2):149–156PubMed
53.
Jung J, Kang Y, Lee YJ et al (2017) Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry. J Pathol Transl Med 51(2):129–136PubMedPubMedCentral
54.
Bao F, Panarelli NC, Rennert H et al (2010) Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol 34(12):1798–1804PubMed
55.
Watanabe Y, Koi M, Hemmi H et al (2001) A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 85(7):1064–1069PubMedPubMedCentral
56.
Ishida Y, Agata Y, Shibahara K et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895PubMedPubMedCentral
57.
The safety and effectiveness of pembrolizumab in KYNOTE-164 study in Japanese application dossier
58.
The safety and effectiveness of pembrolizumab in KYNOTE-158 study in Japanese application dossier
59.
Domingo E, Laiho P, Ollikainen M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41(9):664–668PubMedPubMedCentral
60.
Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191PubMedPubMedCentral
61.
Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779PubMed
62.
Segal NH, Wainberg ZA, Overman MJ et al (2019) Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability-high (MSI-H) tumors. J Clin Oncol. 37(suppl_4):abstr670
63.
Muro K, Van Cutsem E, Narita Y et al (2019) Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 30(1):19–33PubMed
64.
Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378(19):1789–1801PubMed
65.
Romano E, Scordo M, Dusza SW et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28(18):3042–3047PubMedPubMedCentral
66.
Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350PubMed
67.
Aaltonen LA, Peltomäki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54(7):1645–1648PubMed
68.
The safety and effectiveness of pembrolizumab in KYNOTE-016 study, KEYNOTE-164 study (Cohort A), KEYNOTE-012 study, KEYNOTE-028 study, KEYNOTE-158 study in FDA application dossier
69.
Mangold E, Pagenstecher C, Friedl W et al (2005) Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 207(4):385–395PubMed
70.
Wahlberg SS, Schmeits J, Thomas G et al (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62(12):3485–3492PubMed
71.
Bellizzi AM, Frankel WL (2009) Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 16(6):405–417PubMed
72.
73.
Vanderwalde A, Spetzler D, Xiao N et al (2018) Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7(3):746–756PubMedPubMedCentral
74.
Artyomenko A, Sikora M, Lefterova M et al (2018) Microsatellite instability detection by targeted sequencing of cell-free DNA. Ann Oncol 29(suppl_8):abstr 1190P
75.
Deng A, Yang J, Lang J et al (2018) Monitoring microsatellite instability (MSI) in circulating tumor DNA by next-generation DNA-seq. J Clin Oncol 36(suppl_15):abstr 12025
76.
Metadata
Title
Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition
Authors
Saori Mishima
Hiroya Taniguchi
Kiwamu Akagi
Eishi Baba
Yutaka Fujiwara
Akira Hirasawa
Masafumi Ikeda
Osamu Maeda
Kei Muro
Hiroshi Nishihara
Hiroyki Nishiyama
Tadao Takano
Katsuya Tsuchihara
Yasushi Yatabe
Yasuhiro Kodera
Takayuki Yoshino
Publication date
01-02-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 2/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01498-8

Other articles of this Issue 2/2020

International Journal of Clinical Oncology 2/2020 Go to the issue

Original Article

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

Original Article

Clinicopathologic characteristics of malignant non-hematopoietic tumors first presented as an axillary mass with emphasis on occult breast carcinoma

Original Article

Association of MTHFR gene polymorphisms with pancreatic cancer: meta-analysis of 17 case–control studies

Original Article

Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma

Original Article

Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck

Original Article

Factors affecting R0 resection of colorectal cancer with synchronous peritoneal metastases: a multicenter prospective observational study by the Japanese Society for Cancer of the Colon and Rectum
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits